跳至主要内容
临床试验/NL-OMON21139
NL-OMON21139尚未招募不适用

Focus on values to stimulate shared decisions in patients with thyroid cancer: A multifacetedCOMmunication BOoster (COMBO)

Radboudumc0 个研究点目标入组 128 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
Radboudumc
入组人数
128

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • •Total thyroidectomy vs hemithyroidectomy:
  • •-patients with nodules >1 cm and <4 cm, with cytology result suspicious or malignant (Bethesda 5 or 6) with no clinical or radiological evidence of pathological lymph nodes and/or distant metastases before the primary (diagnostic) surgery
  • •-patients with histologically (after diagnostic hemithyroidectomy) proven TC but are defined as low-risk according to the ATA
  • •classification(97,98) -patients with multifocal TC
  • •-patients with incomplete resection of the primary tumor
  • •-patients with ATA defined intermediate risk or high risk
  • •No treatment with RAI vs. treatment with RAI:
  • •-patients with ATA defined low-risk (98) and patients with multifocal papillary TC in the absence of other adverse features.
  • •Active surveillance vs. systemic treatment:
  • •-patients with asymptomatic or mildly symptomatic RAI-refractory (slowly) progressive metastatic disease

排除标准

  • •Total thyroidectomy vs hemithyroidectomy:
  • •-patients with multifocal TC
  • •-patients with incomplete resection of the primary tumor
  • •-patients with ATA defined intermediate risk or high risk
  • •No treatment with RAI vs. treatment with RAI:
  • •-patients with ATA defined intermediate risk or high risk
  • •Active surveillance vs. systemic treatment:
  • •-patients with coexisting conditions that do not allow prescription of TKI’s

研究者

发起方
Radboudumc

相似试验